Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases

Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
COVID-19 Programs
COVISTIX™ (diagnostic) Rapid Antigen Test 0%* Emergency Use Authorization (EUA) in Mexico (COFEPRIS), Brazil (ANVISA), and CE Marked in Europe COVI-DROPS™ (treatment) Neutralizing Antibody (Intranasal) in Outpatients 60.2%* COVI-AMG™ (treatment) Neutralizing Antibody (IV) in Outpatients 60.2%* COVI-SHIELD™ (treatment) Neutralizing Antibody (IV and IN) in Outpatients and Inpatients 20%* ABIVERTINIB (treatment) Severe COVID-19 in ICU Patients 82%* Pivotal Trial Pending FDA Clearance COVI-MSC (treatment) ARDS due to COVID-19 in ICU Patients 82%* Pivotal Trial in Brazil Mpro Inhibitor (oral pill) Anti-viral 20%* Omicron mRNA Vaccine Vaccine 20%*
Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Immunotherapy
Abivertinib NSCLC 82%* Abivertinib B Cell Lymphomas 60.2%* Abivertinib Prostate 20%* Abivertinib Lupus 20%* Abivertinib MS 20%* Abivertinib GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* *In Partnership with Lee’s Pharm in China PD-L1 (STI-3031)** Cervical Cancer 82%* **In US and in partnership with ImmuneOncia in Korea CD47 Solid Tumors 40%* CD38 DAR-T Multiple Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, and esophageal 40%* TROP2 ADC* Solid Tumors 40%* * In China Seprehvec™ oncolytic virus Solid Tumors; CNS Tumors 40%* BCMA ADC Liquid Tumors 20%* Bevacizumab-ADNAB™ Endometrial Cancer 40%* In partnership with Mayo Clinic Bevacizumab-ADNAB™ Ovarian Cancer 40%* In partnership with Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* In partnership with Mayo Clinic
Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Pain
ZTlido™ 1.8% Postherpetic Neuralgia - PHN 99.8%* SP-102 Lumbar Radicular/Sciatica Pain 82%* SP-103 Acute Back Pain 40%* SP-104 Fibromyalgia 20%* RTX (resiniferatoxin) Epidural injection Intractable Pain in Advanced Cancer 60.3%* Orphan designation RTX (resiniferatoxin) Intra-articular route Moderate to Severe Knee OA Pain 60.2%*
Key Programs	Indication	Preclinical	Phase I	Phase II	Phase III/Pivotal	FDA Approval
Lymphatic Delivery
Sofusa® anti-TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Cutaneous T-Cell Lymphoma (CTCL) 40%* Sofusa® anti-PD-1 Melanoma 40%* In partnership with Mayo Clinic

COVID-19 Programs
Key Programs (Indication)	Phase
COVISTIX™ (diagnostic) FDA EUA COVIDROPS™ (treatment) Ph II COVI-AMG™ (treatment) Ph II COVISHIELD™ (treatment) Preclinical ABIVERTINIB (treatment) Ph III COVI-MSC (treatment) Ph III Mpro Inhibitor (oral pill) (anti-viral) Preclinical Omicron mRNA Vaccine (vaccine) Preclinical

Immunotherapy
Key Programs (Indication)	Phase
Abivertinib (NSCLC) Ph III Abivertinib (B Cell Lymphomas) Ph II Abivertinib (Prostate) Preclinical Abivertinib (Lupus) Preclinical Abivertinib (MS) Preclinical Abivertinib (GvHD) Preclinical PD-L1 (Socazolimab)*(SCLC) Ph III PD-L1 (STI-3031)** (Cervical Cancer) Ph III CD47 (Solid Tumors) Ph I CD38 CAR-T (Multiple Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, and esophageal) Ph I TROP2 ADC* (Solid Tumors) Ph I Seprehvec™ oncolytic virus (Solid Tumors; CNS Tumors) PH I BCMA ADC (Liquid Tumors) Preclinical Bevacizumab-ADNAB™ (Endometrial Cancer) Ph I Bevacizumab-ADNAB™ (Ovarian Cancer) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I

Pain
Key Programs (Indication)	Phase
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) FDA Approval SP-102 (Lumbar Radicular/Sciatica Pain) Ph III SP-103 (Acute Back Pain) Ph I SP-104 (Fibromyalgia) Preclinical RTX (resiniferatoxin) Epidural injection (Intractable Pain in Advanced Cancer) Ph II RTX (resiniferatoxin) Intra-articular route (Moderate to Severe OA Knee Pain) Ph II

Lymphatic Delivery
Key Programs (Indication)	Phase II
Sofusa® anti-TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL)) Ph I Sofusa® anti-PD-1 (Melanoma) Ph I